Hetlosar Tablets / Film-coated
Losartan Potassium
50mg
Nexgen Pharma FZ LLC
| Pack size | 30's (10's Blister x 3) |
|---|---|
| Dispensing mode | POM |
| Source | UAE |
| Agent | NEW MEDICAL CENTRE |
| Retail Price | 37.50 AED |
Available as:
Indications
Hetlosar Tablets / Film-coated is used for:
Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure, Hypertensive Patients with Left Ventricular Hypertrophy
Adult Dose
Oral
Hypertension
Adult: 50 mg once daily, may increase to 100 mg/day as single dose or in 2 divided doses if needed. Patients w/ intravascular volume depletion: Initially, 25 mg once daily.
Diabetic nephropathy in Type 2 diabetes mellitus
Adult: Initially, 50 mg once daily, may increase to 100 mg once daily depending on BP response.
Heart failure, Hypertension and Left Ventricular Hypertrophy, Stroke risk reduction of hypertensive or LVH patients:
Adult: Initially, 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should be added and/or the dose of Losartan should be increased to 100 mg once daily followed by an increase in hydrochlorothiazide to 25 mg once daily based on blood pressure response
Child Dose
Hypertension
<6 years: Safety and efficacy not established
Child: >6 yr 20-50 kg: Initially, 0.7 mg/kg. Max: 50 mg/day;
>50 kg: Initially, 1.4 mg/kg. Max: 100 mg/day.
Renal Dose
Renal impairment: CrCl <20 ml/min: Initially 25 mg once daily.
Administration
May be taken with or without food.
Contra Indications
Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug. Concomitant use w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min). Severe hepatic impairment. Pregnancy.
Precautions
Volume-depleted patients including patients on high-dose diuretics. Patients w/ bilateral renal artery stenosis , aortic or mitral stenosis. Renal and mild to moderate hepatic impairment. Lactation. Monitoring Parameters Monitor BP, electrolytes and renal function.
Lactation: Unknown if excreted in milk; not recommended
Pregnancy-Lactation
Pregnancy
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death
When pregnancy is detected, discontinue treatment as soon as possible
Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus
Animal data
May produce adverse effects in rat fetuses and neonates, including decreased body weight, delayed physical and behavioral development, mortality and renal toxicity
With the exception of neonatal weight gain (which was affected at doses as low as 10 mg/kg/day), doses associated with these effects exceeded 25 mg/kg/day (~3x the maximum recommended human dose of 100 mg on a mg/m2 basis)
Significant levels of losartan and its active metabolite were present in rat fetal plasma during late gestation and in rat milk
Lactation
Unknown whether drug is excreted in human milk, but significant levels of losartan and its active metabolite were shown to be present in rat milk
Interactions
May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Adverse Effects
Side effects of Losartan Potassium :
>10%
Fatigue (14%), Hypoglycemia (14%), Anemia (14%), Urinary tract infection (UTI) (13%), Chest pain (12%), Weakness (14%), Diarrhea (2-15%), Cough; incidence higher in previous cough related to angiotensin-converting enzyme (ACE) inhibitor therapy (3-11%)
1-10%
Upper respiratory tract infection (8%), Hypotension (7%), Dizziness (4%), Cellulitis (7%), Gastritis (5%), Nausea (2%)
Frequency Not Defined
Angioedema, Edema/swelling, Hypotension in hypovolemic or diuretic-using patients, Asthenia, Headache, Malaise, Nausea, Abdominal pain, Hyperkalemia, Back pain, Worsening renal failure
Mechanism of Action
Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
Note
Hetlosar 50mg Tablets / Film-coated manufactured by Nexgen Pharma FZ LLC. Its generic name is Losartan Potassium. Hetlosar is availble in United Arab Emirates.
Farmaco UAE drug index information on Hetlosar Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Losartan Potassium :
Tablets / Film-coated
Saranto
50mg
Aurobindo Pharma FZ LLC
Tablets / Film-coated
Saranto
100mg
Aurobindo Pharma FZ LLC
Tablets / Film-coated
Lupisar
100mg/ml
LUPIN MIDDLE EAST FZ LLC
Tablets / Film-coated
Lupisar
50mg/ml
LUPIN MIDDLE EAST FZ LLC
Tablets / Film-coated
Stravis
Losartan potassium 100mg
Riyadh Pharma (Medical and Cosmetic Products Company Ltd.)